Overall, the study included data from nearly 950,000 patients with T1D
They represent thousands of people watching their hair thin while pursuing a healthier weight, caught between the undeniable benefits of weight loss therapy and an unexpected cosmetic consequence that nobody prepared them for
Developing drugs for MASH is challenging due to the need to address multiple disease aspectsfat accumulation, inflammation, and fibrosissimultaneously
Patients should discuss potential benefits, risks, and side effects with their healthcare provider before and during treatment
Table 2B A review of preclinical studies of GLP-1 and GLP-1RAs in stroke
The first GLP-1 receptor agonist, exenatide was approved by the FDA for the treatment of T2DM in 2005